Claudy A L, Roche H
Ann Dermatol Venereol. 1981;108(10):765-7.
The treatment of recalcitrant multiple verrucae by sensitization to DNCB has been successfully used as shown in a previous study. Owing to the mutagenic effect of DNCB in Ames test, we tried a new non-mutagenic compound, SADBE to treat patients with multiple recurring warts. The study comprised 18 patients whose informed consent was obtained. They were sensitized to SADBE with a 2 p. 100 solution applied once and then treated with a 0.1 p. 100 solution weekly. The solution was applied by means of a swab on the warts. The concentration was adjusted to the patient's reactivity in order to maintain a mild contact dermatitis. The duration of treatment ranged from 4 to 13 weeks. Our results showed tat complete resolution of warts occurred in only 2 out of 18 patients. Side effects were negligible. In conclusion, we do not support the use of SADBE for treating multiple recurring warts.
如先前一项研究所显示，通过对二硝基氯苯（DNCB）致敏来治疗顽固性多发性疣已获成功应用。鉴于DNCB在艾姆斯试验中的致突变作用，我们尝试使用一种新的非致突变化合物——二乙酰氧基二丁基醚（SADBE）来治疗多发性复发性疣患者。该研究纳入了18名获得知情同意的患者。他们用2%的溶液对SADBE进行致敏，涂抹一次，然后每周用0.1%的溶液进行治疗。溶液用棉签涂抹在疣体上。根据患者的反应性调整浓度，以维持轻度接触性皮炎。治疗持续时间为4至13周。我们的结果显示，18名患者中仅有2名疣体完全消退。副作用可忽略不计。总之，我们不支持使用SADBE治疗多发性复发性疣。
